SCHEMBL13297969

SCHEMBL13297969

CN(C)CCN1C(=O)c2cccc3cc4cccc(NC(=O)Oc5ccc(F)cc5)c4c(c23)C1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HEXA P06865 1/20 0.47
▸ HEXB P07686 1/20 0.47
▸ FTO Q9C0B1 3/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ PABPC1 P11940 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ PLK1 P53350 3/20 0.42
▸ POLB P06746 2/20 0.41
▸ NR1I2 O75469 1/20 0.41
▸ AHR P35869 1/20 0.41
▸ RAD52 P43351 1/20 0.41
▸ RCE1 Q9Y256 1/20 0.41
▸ CYP1A2 P05177 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ HPGD P15428 1/20 0.39
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13297958 0.92 HEXA (0.50) HEXAHEXBFTOCYP2D6SMN1; SMN2
SCHEMBL13297944 0.87 HEXA (0.55) HEXAHEXBFTOCYP2D6SMN1; SMN2
SCHEMBL13297957 0.84 HEXA (0.52) HEXAHEXBFTOCYP2D6SMN1; SMN2
SCHEMBL13297981 0.83 HEXA (0.48) HEXAHEXBFTOCYP2D6SMN1; SMN2
SCHEMBL13297972 0.83 HEXA (0.57) HEXAHEXBFTOCYP2D6SMN1; SMN2
SCHEMBL3293589 0.83 HEXA (0.57) HEXAHEXBFTOCYP2D6SMN1; SMN2
SCHEMBL3303914 0.82 HEXA (0.54) HEXAHEXBFTOCYP2D6SMN1; SMN2
SCHEMBL13297975 0.82 HEXA (0.49) HEXAHEXBFTOCYP2D6SMN1; SMN2
SCHEMBL13297973 0.81 HEXA (0.48) HEXAHEXBFTOCYP2D6SMN1; SMN2
SCHEMBL13297979 0.81 FTO (0.49) HEXAHEXBFTOCYP2D6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741337-B2 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom UNIBIOSCREEN S.A. (BE) 2010-06-22 — — US disclosed
US-7741337-B2 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom UNIBIOSCREEN S.A. (BE) 2010-06-22 — — US disclosed
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom UNIBIOSCREEN S.A. (BE) 2008-11-27 — — US disclosed
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom UNIBIOSCREEN S.A. (BE) 2008-11-27 — — US disclosed
EP-1787985-A1 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom Unibioscreen S.A. (BE) 2007-05-23 — — EP disclosed
WO-2007054292-A2 AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM UNIBIOSCREEN S.A. (BE) 2007-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 HEXA 1944/4885HEXB 2802/4885FTO 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback